Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azoximer bromide
- Development stage
- Phase 3
- Lead developer
- Petrovax Pharm
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous, Sublingual, Rectal, Intranasal, Vaginal, Topical
01
Overview
Azoximer bromide, marketed under the brand name Polyoxidonium, is a synthetic high-molecular-weight immunomodulator developed by NPO Petrovax Pharm. Chemically, it is a copolymer of N-oxide 1,4-ethylenepiperazine and (N-carboxymethyl)-1,4-ethylenepiperazine bromide. The drug exhibits a multifaceted mechanism of action, primarily stimulating innate immunity by enhancing the activity of macrophages, neutrophils, and natural killer (NK) cells. Additionally, it possesses antioxidant and detoxifying properties, which help reduce the systemic toxicity of other therapeutic agents. Azoximer bromide is widely used in Russia and CIS countries for the treatment and prevention of infectious diseases, including acute respiratory infections and COVID-19, and has been investigated as a concomitant therapy in oncology (e.g., melanoma) to improve patient survival and time to progression.
- Brand names
- Polyoxidonium
- Other names
- azoximer bromidePolyoxidoin
Beyond the preview
Go deeper on azoximer bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azoximer bromide.